Literature DB >> 22159517

Potent antitumor effects of combination therapy with IFNs and monocytes in mouse models of established human ovarian and melanoma tumors.

Hideyuki Nakashima1, Kotaro Miyake, Christopher R Clark, Joseph Bekisz, Joel Finbloom, Syed R Husain, Samuel Baron, Raj K Puri, Kathryn C Zoon.   

Abstract

Interferon-activated monocytes are known to exert cytocidal activity against tumor cells in vitro. Here, we have examined whether a combination of IFN-α2a and IFN-γ and human monocytes mediate significant antitumor effects against human ovarian and melanoma tumor xenografts in mouse models. OVCAR-3 tumors were treated i.t. with monocytes alone, IFN-α2a and IFN-γ alone or combination of all three on day 0, 15 or 30 post-tumor implantation. Mice receiving combination therapy beginning day 15 showed significantly reduced tumor growth and prolonged survival including complete regression in 40% mice. Tumor volumes measured on day 80 in mice receiving combination therapy (206 mm(3)) were significantly smaller than those of mice receiving the IFNs alone (1,041 mm(3)), monocytes alone (1,111 mm(3)) or untreated controls (1,728 mm(3)). Similarly, combination therapy with monocytes and IFNs of much larger tumor also inhibited OVCAR-3 tumor growth. Immunohistochemistry studies showed a large number of activated macrophages (CD31(+)/CD68(+)) infiltrating into OVCAR-3 tumors and higher densities of IL-12, IP10 and NOS2, markers of M1 (classical) macrophages in tumors treated with combination therapy compared to the controls. Interestingly, IFNs-activated macrophages induced apoptosis of OVCAR-3 tumor cells as monocytes alone or IFNs alone did not mediate significant apoptosis. Similar antitumor activity was observed in the LOX melanoma mouse model, but not as profound as seen with the OVCAR-3 tumors. Administration of either mixture of monocytes and IFN-α2a or monocytes and IFN-γ did not inhibit Lox melanoma growth; however, a significant inhibition was observed when tumors were treated with a mixture of monocytes, IFN-α2a and IFN-γ. These results indicate that monocytes and both IFN-α2a and IFN-γ may be required to mediate profound antitumor effect against human ovarian and melanoma tumors in mouse models.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22159517      PMCID: PMC3467013          DOI: 10.1007/s00262-011-1152-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  50 in total

1.  Monocyte heterogeneity and innate immunity.

Authors:  Philip R Taylor; Siamon Gordon
Journal:  Immunity       Date:  2003-07       Impact factor: 31.745

2.  A novel population of Gr-1+-activated macrophages induced during acute toxoplasmosis.

Authors:  Dana G Mordue; L David Sibley
Journal:  J Leukoc Biol       Date:  2003-09-12       Impact factor: 4.962

Review 3.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

Review 4.  Macrophage-directed tumour immunotherapy revisited--past and future of an old doctor's dilemma.

Authors:  R Andreesen
Journal:  Res Immunol       Date:  1993-05

Review 5.  Therapy of cancer metastasis by activation of the inducible nitric oxide synthase.

Authors:  K Xie; I J Fidler
Journal:  Cancer Metastasis Rev       Date:  1998-03       Impact factor: 9.264

6.  Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro.

Authors:  Samuel Baron; Joel Finbloom; Julie Horowitz; Joseph Bekisz; Angel Morrow; Tongmao Zhao; Samuel Fey; Hana Schmeisser; Corey Balinsky; Kotaro Miyake; Christopher Clark; Kathryn Zoon
Journal:  J Interferon Cytokine Res       Date:  2011-02-16       Impact factor: 2.607

7.  Immunotherapy of a murine lymphoma by adoptive transfer of syngeneic macrophages activated with bisantrene.

Authors:  B S Wang; A L Lumanglas; F E Durr
Journal:  Cancer Res       Date:  1986-02       Impact factor: 12.701

8.  Activation of Kupffer cells inhibits tumor growth in a murine model system.

Authors:  George G Chen; Wan Y Lau; Paul B S Lai; Ying S Chun; Ernest C W Chak; Billy C S Leung; Isa K Y Lam; Janet F Y Lee; Albert K K Chui
Journal:  Int J Cancer       Date:  2002-06-10       Impact factor: 7.396

9.  How does interferon inhibit tumour growth?

Authors:  I Gresser
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1982-09-24       Impact factor: 6.237

Review 10.  Immune-mediated dormancy: an equilibrium with cancer.

Authors:  Michele W L Teng; Jeremy B Swann; Catherine M Koebel; Robert D Schreiber; Mark J Smyth
Journal:  J Leukoc Biol       Date:  2008-05-30       Impact factor: 4.962

View more
  9 in total

1.  Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatin.

Authors:  Chase L Johnson; Daniel S Green; Kathryn C Zoon
Journal:  J Interferon Cytokine Res       Date:  2014-07-28       Impact factor: 2.607

2.  Interferon-γ polymorphism and hepatocellular carcinoma susceptibility: a meta analysis.

Authors:  Jing Sun; Kai Liao; Yuefei Wang; Leida Zhang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

3.  Type I Interferon-Mediated Induction of Antiviral Genes and Proteins Fails to Protect Cells from the Cytopathic Effects of Sendai Virus Infection.

Authors:  Jacquelyn R Bedsaul; Luna A Zaritsky; Kathryn C Zoon
Journal:  J Interferon Cytokine Res       Date:  2016-08-10       Impact factor: 2.607

4.  Monocyte and interferon based therapy for the treatment of ovarian cancer.

Authors:  Daniel S Green; Ana T Nunes; Christina M Annunziata; Kathryn C Zoon
Journal:  Cytokine Growth Factor Rev       Date:  2016-03-15       Impact factor: 7.638

Review 5.  Immunomodulatory effects of interferons in malignancies.

Authors:  Joseph Bekisz; Yuki Sato; Chase Johnson; Syed R Husain; Raj K Puri; Kathryn C Zoon
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

6.  Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer.

Authors:  Daniel S Green; Syed R Husain; Chase L Johnson; Yuki Sato; Jing Han; Bharat Joshi; Stephen M Hewitt; Raj K Puri; Kathryn C Zoon
Journal:  Immunotherapy       Date:  2019-04       Impact factor: 4.040

7.  A conditional zebrafish MITF mutation reveals MITF levels are critical for melanoma promotion vs. regression in vivo.

Authors:  James A Lister; Amy Capper; Zhiqiang Zeng; Marie E Mathers; Jennifer Richardson; Karthika Paranthaman; Ian J Jackson; E Elizabeth Patton
Journal:  J Invest Dermatol       Date:  2013-07-05       Impact factor: 8.551

8.  Production of a cellular product consisting of monocytes stimulated with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for human use.

Authors:  Daniel S Green; Ana T Nunes; Kevin W Tosh; Virginia David-Ocampo; Vicki S Fellowes; Jiaqiang Ren; Jianjian Jin; Sue-Ellen Frodigh; Chauha Pham; Jolynn Procter; Celina Tran; Irene Ekwede; Hanh Khuu; David F Stroncek; Steven L Highfill; Kathryn C Zoon; Christina M Annunziata
Journal:  J Transl Med       Date:  2019-03-14       Impact factor: 5.531

9.  A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Authors:  Daniel S Green; Ana T Nunes; Virginia David-Ocampo; Irene B Ekwede; Nicole D Houston; Steven L Highfill; Hanh Khuu; David F Stroncek; Seth M Steinberg; Kathryn C Zoon; Christina M Annunziata
Journal:  J Transl Med       Date:  2018-07-16       Impact factor: 5.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.